IntelGenx Enters into a Development and License Agreement with Covenant Animal Health to Develop VetaFilm-Based Products for Animal Use
Shots:
- IntelGenx signed an agreement with Covenant Animal Health Partners for the development & manufacturing of products based on IntelGenx’s VetaFilm drug delivery platform
- As per the agreement, Convent Animal Health received the exclusive license to impose VetaFilm to develop products for non-human applications & thereby will fund all the costs related to the development & manufacturing of VetaFilm-based products
- On the other hand, IntelGenx will receive royalties on the global sales of the product & will manufacture the product globally for clinical development. Additionally, IntelGenx expects to enter into subsequent supply agreements to supply the products to Covenant Animal Health
Ref: Intelgenx | Image: Intelgenx
Related News:- IntelGenx’s Rizafilm Receives the US FDA’s Approval for the Treatment of Acute Migraine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
